O2h has a track record of nurturing and investing in emerging life science and tech companies, covering biotech, small molecule, biologics, digital health, software and social enterprise.
Opal Oncology is a drug discovery company incorporated in 2012 and is based in Cambridge, UK. We have a vision for discovering and in-licensing small molecule cancer therapies. Read More
o2h is a highly reputed service provider of mg/g scale discovery chemistry. We have partnered with a range of well known pharmaceutical and biotechnology companies from Europe, USA and Japan. Read More
Talent Advocate (TA) is an employee social media advocacy platform uniquely placed to serve the corporate talent acquisition market. Read More
Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Read More
From initial concept to the delivery of candidate drugs - we're a drug discovery company specialising in cutting-edge cancer treatment Read More
PhoreMost® has developed a next-generation phenotypic screening platform called 'SITESEEKER®' to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited. Read More
Talisman Therapeutics, a spinout from the University of Cambridge, is a stem cell research and development company committed to revolutionising the discovery of treatments for Alzheimer's disease. Read More
Zephx is an innovation led technology company that designs gamification for medical devices used to treat respiratory conditions. Read More
Science-led ambitious start up focused on the development of antibacterial compounds with novel mechanisms of action against drug resistant organisms
Absynth Biologics discovers and develops vaccines and antibodies to prevent and treat bacterial infections; based on a platform for identifying novel protein antigen targets that harness the immune system Read More
Acacia Pharma is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment. Read More
LaborVoices provides global brands and their supply chains what has been missing: an early warning system based on direct feedback from workers, by repeatedly polling workers through their mobile phones. Read More
IOTA Pharmaceuticals has been established to bring you the tools and technologies for Fragment-based Drug Discovery(FBDD) and High-content Screening(HCS). Read More
Small Pharma is forging a new path in pharmaceutical development by bridging the gap between academia and industry. Read More
Oxford Drug Design (formerly InhibOx) is a biotechnology company focused on internal drug discovery. The lead antibacterial programme has identified compounds with the potential to be developed into therapies for Gram-negative bacterial infections, including against strains resistant to multiple current antibacterial drug classes. Read More
A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides Read More
The Repositive platform enables researchers to browse through multiple repositories for the human genomic data they need to power their research. Read More
Privitar facilitates broader use of data while adopting an uncompromising approach to protecting confidential information. Read More
Oxford Drug Design Ltd (previously known as InhibOx), the leading computer aided drug design and 3D chemical database company, is pleased to announce that it has com...
O2h update: Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development of an eye – drop treatment for wet age–...
O2h Discovery is pleased to announce a 10 FTE Synthetic Chemistry collaboration with Heptares. Giles Brown, Director of Medicinal Chemistry: "Heptares is pleased to expand its discovery chemistry c...